NASH Drug Cost Concerns On Level With HCV Treatments For Payers
This article was originally published in The Pink Sheet Daily
OptumRx, Harvard Pilgrim watching closely as Intercept’s Ocaliva nears market entry with claim for primary biliary cholangitis; use restrictions against off-label use in NASH are likely.
You may also be interested in...
Public Company Edition: Madrigal and Galmed shares more than doubled after reporting what were viewed as positive results in mid-stage NASH studies, with Madrigal going on to raise $300m on the back of the data. Not all is well for publicly traded firms, however, as Advaxis and Flex Pharma reveal layoffs.
A new epidemiological analysis suggests the increasing number of patients from across the globe with some form of non-alcoholic fatty liver disease promises an effective therapy would be a welcome addition to the armamentarium of liver disease specialists.
Indication-specific pricing could address 'tension' between initial pricing of Ocaliva for orphan condition and later use in large patient population, according to expert roundtable convened by Institute for Clinical and Economic Review.